**Infectious Disease Agents: Antivirals – Hepatitis C Agents**

<table>
<thead>
<tr class="header">
<th><strong>Criteria Title</strong></th>
<th>Infectious Disease Agents: Antivirals – Hepatitis C Agents</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Criteria Subtitle</strong></td>
<td>All Products</td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td><strong>Approval Level</strong></td>
<td>GCNSeqNo</td>
<td></td>
<td></td>
</tr>
<tr class="odd">
<td><p><strong>Products</strong></p>
<table>
<thead>
<tr class="header">
<th>Preferred</th>
<th></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Non-Preferred</td>
<td></td>
</tr>
<tr class="even">
<td>Brand</td>
<td></td>
</tr>
<tr class="odd">
<td>Generic</td>
<td></td>
</tr>
<tr class="even">
<td>Other</td>
<td></td>
</tr>
</tbody>
</table></td>
<td>Drug Name</td>
<td>Corresponding Code (s)</td>
<td>Type of Code (GCNSeqNo, HICL, NDC)</td>
</tr>
<tr class="even">
<td></td>
<td>HARVONI</td>
<td>072926</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>HARVONI</td>
<td>080162</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>HARVONI</td>
<td>080179</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>HARVONI</td>
<td>080180</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td><p>LEDIPASVIR/</p>
<p>SOFOSBUVIR</p></td>
<td>072926</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>MAVYRET</td>
<td>077637</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>MAVYRET</td>
<td>082438</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>PEGASYS</td>
<td>050736</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>PEGASYS</td>
<td>051151</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>RIBAVIRIN</td>
<td>048664</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>RIBAVIRIN</td>
<td>051637</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>RIBAVIRIN</td>
<td>060100</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>SOFOSBUVIR/VELPATASVIR</td>
<td>076305</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>SOFOSBUVIR/VELPATASVIR</td>
<td>081610</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>SOFOSBUVIR/VELPATASVIR</td>
<td>082395</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>SOFOSBUVIR/VELPATASVIR</td>
<td>082396</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>SOVALDI</td>
<td>071748</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>SOVALDI</td>
<td>080163</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>SOVALDI</td>
<td>080164</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>SOVALDI</td>
<td>080165</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>VOSEVI</td>
<td>077584</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>ZEPATIER</td>
<td>075514</td>
<td>GCNSeqNo</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr class="header">
<th><strong>Sequence Number</strong> </th>
<th><strong>Question ID</strong> </th>
<th><strong>Default Next Question ID</strong> </th>
<th><strong>Question Type</strong> </th>
<th><strong>Question Text</strong> </th>
<th><strong>Choice Text</strong> </th>
<th><strong>Next Question ID</strong> </th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>1</td>
<td>1000</td>
<td></td>
<td>Select and Free Text</td>
<td><p>Has the provider submitted documentation of the patient’s active HCV infection verified by viral load within 180 days (HCV RNA value and date)?</p>
<p>If yes, please enter the HCV RNA count (million IU/mL) and date of verification.</p></td>
<td>Y</td>
<td>1001</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1235</td>
</tr>
<tr class="odd">
<td>2</td>
<td>1001</td>
<td></td>
<td>Select and Free Text</td>
<td><p>Has the provider submitted documentation of the patient’s HCV genotype (verified by lab genotype)?</p>
<p>If yes, please submit documentation.</p></td>
<td>Y</td>
<td>1002</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1235</td>
</tr>
<tr class="odd">
<td>3</td>
<td>1002</td>
<td></td>
<td>Select</td>
<td>What is the patient’s genotype?</td>
<td>1a</td>
<td>1003</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1b</td>
<td>1003</td>
</tr>
<tr class="odd">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2</td>
<td>1003</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3</td>
<td>1003</td>
</tr>
<tr class="odd">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>4</td>
<td>1003</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>5</td>
<td>1003</td>
</tr>
<tr class="odd">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>6</td>
<td>1003</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Other</td>
<td>1235</td>
</tr>
<tr class="odd">
<td>4</td>
<td>1003</td>
<td></td>
<td>Select and Free Text</td>
<td><p>Has the provider submitted documentation of the patient’s hepatitis fibrosis stage?</p>
<p>If yes, please submit fibrosis stage, date, and method(s) used.</p></td>
<td>Y</td>
<td>1004</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1235</td>
</tr>
<tr class="odd">
<td>5</td>
<td>1004</td>
<td></td>
<td>Select</td>
<td>Is the patient scheduled to receive an HCVNS3 protease inhibitor (i.e. grazoprevir, voxilaprevir, glecaprevir)?</td>
<td>Y</td>
<td>1005</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1006</td>
</tr>
<tr class="odd">
<td>6</td>
<td>1005</td>
<td></td>
<td>Select and Free Text</td>
<td><p>Has the patient been assessed for a history of decompensated liver disease and liver disease severity using the Child-Turcotte-Pugh (CTP) score if cirrhosis is determined to be likely present (as evidenced by clinical findings, radiology, Metavir fibrosis score of F4, pathology findings or other laboratory markers (FibroTest/FibroSure/FIB-4 index)?</p>
<p>If yes, please provide documentation to support the request.</p></td>
<td>Y</td>
<td>1006</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1235</td>
</tr>
<tr class="odd">
<td>7</td>
<td>1006</td>
<td></td>
<td>Select</td>
<td>Has the prescriber discussed the importance of adherence to treatment plan, office visits, lab monitoring, imaging, procedures and to taking requested regimen as prescribed?</td>
<td>Y</td>
<td>1007</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1235</td>
</tr>
<tr class="odd">
<td>8</td>
<td>1007</td>
<td></td>
<td>Select</td>
<td>Does the patient have a limited life expectancy (less than 12 months) due to non-liver-related comorbid conditions?</td>
<td>Y</td>
<td>1235</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1008</td>
</tr>
<tr class="odd">
<td>9</td>
<td>1008</td>
<td></td>
<td>Select</td>
<td>Does the patient’s regimen include ribavirin?</td>
<td>Y</td>
<td>1009</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1013</td>
</tr>
<tr class="odd">
<td>10</td>
<td>1009</td>
<td></td>
<td>Select</td>
<td><p>Does the patient have ANY of the following:</p>
<ul>
<li><p>CrCl less than 50 mL/min (unless dose is adjusted)</p></li>
<li><p>Hypersensitivity to ribavirin</p></li>
<li><p>History of severe or unstable cardiac disease</p></li>
<li><p>Pregnant women and men with pregnant partners</p></li>
<li><p>Diagnosis of hemoglobinopathy (e.g. thalassemia major, sickle cell anemia)</p></li>
<li><p>Baseline platelet count less than 70,000 cells/mm<sup>3</sup></p></li>
<li><p>ANC less than 1,500 cells/mm<sup>3</sup></p></li>
<li><p>Hb less than 12gm/dl in women or less than 13g/dL in men</p></li>
</ul></td>
<td>Y</td>
<td>1010</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1011</td>
</tr>
<tr class="odd">
<td>11</td>
<td>1010</td>
<td></td>
<td>Free Text</td>
<td><p>Please indicate which of the following apply to the patient:</p>
<p>1. CrCl less than 50 mL/min (unless dose is adjusted)</p>
<p>2. Hypersensitivity to ribavirin</p>
<p>3. History of severe or unstable cardiac disease</p>
<p>4. Pregnant women and men with pregnant partners</p>
<p>5. Diagnosis of hemoglobinopathy (e.g. thalassemia major, sickle cell anemia)</p>
<p>6. Baseline platelet count less than 70,000 cells/mm<sup>3</sup></p>
<p>7. ANC less than 1,500 cells/mm<sup>3</sup></p>
<p>8. Hb less than 12gm/dl in women or less than 13g/dL in men</p></td>
<td>END (Pending Manual Review)</td>
<td></td>
</tr>
<tr class="even">
<td>12</td>
<td>1011</td>
<td></td>
<td>Select</td>
<td>Is the patient a woman of childbearing potential or a male patient with a female partner of childbearing potential?</td>
<td>Y</td>
<td>1012</td>
</tr>
<tr class="odd">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1013</td>
</tr>
<tr class="even">
<td>13</td>
<td>1012</td>
<td></td>
<td>Select</td>
<td><p>Has the provider confirmed all of the following:</p>
<ul>
<li><p>Patient is not pregnant (or a male with a pregnant female partner) and not planning to become pregnant during treatment or within 6 months of stopping</p></li>
<li><p>Agreement that partners will use two forms of effective contraception during treatment and for at least 6 months after stopping</p></li>
</ul>
<ul>
<li><p>Verification that monthly pregnancy tests will be performed throughout treatment</p></li>
</ul></td>
<td>Y</td>
<td>1013</td>
</tr>
<tr class="odd">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1235</td>
</tr>
<tr class="even">
<td>14</td>
<td>1013</td>
<td></td>
<td>Select</td>
<td>What is the patient’s treatment status?</td>
<td>Treatment naïve</td>
<td>1014</td>
</tr>
<tr class="odd">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Treatment experienced</td>
<td>2000</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Re-infection of Allograft Liver after Transplant</td>
<td>3000</td>
</tr>
<tr class="odd">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Decompensated Cirrhosis</td>
<td>4000</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Other</td>
<td>1235</td>
</tr>
<tr class="odd">
<td>15</td>
<td>1014</td>
<td></td>
<td>Select</td>
<td>What is the patient’s cirrhosis status?</td>
<td>No cirrhosis</td>
<td>1015</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Compensated cirrhosis</td>
<td>1016</td>
</tr>
<tr class="odd">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Other</td>
<td>1235</td>
</tr>
<tr class="even">
<td>16</td>
<td>1015</td>
<td></td>
<td>Select and Free Text</td>
<td><p>The Ohio Department of Medicaid allows the following treatment regimens. Please select the regimen you are requesting.</p>
<p>If other, please enter drug regimen requested, including drug names, doses, and duration of treatment.</p></td>
<td>Mavyret 100/40 mg, three (3) tablets daily for 8 weeks</td>
<td>1231</td>
</tr>
<tr class="odd">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>sofosbuvir/velpatasvir 400/100 mg, one tablet daily for 12 weeks</td>
<td>1231</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Other</td>
<td>1228</td>
</tr>
<tr class="odd">
<td>17</td>
<td>1016</td>
<td></td>
<td>Select and Free Text</td>
<td><p>The Ohio Department of Medicaid allows the following treatment regimens. Please select the regimen you are requesting.</p>
<p>If other, please enter drug regimen requested, including drug names, doses, and duration of treatment.</p></td>
<td>Mavyret 100/40 mg, three (3) tablets daily for 8 weeks (GT4 WITH HIV coinfection, IDSA/AASLD guidelines recommend 12 weeks of therapy)</td>
<td>1231</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>sofosbuvir/velpatasvir 400/100, one tablet daily for 12 weeks (for GT3, add weight based RBV if Y93H positive)</td>
<td>1231</td>
</tr>
<tr class="odd">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Other</td>
<td>1228</td>
</tr>
<tr class="even">
<td>18</td>
<td>2000</td>
<td></td>
<td>Select</td>
<td>Please select the regimen previously failed:</td>
<td>Sofosbuvir-based regimen</td>
<td>2001</td>
</tr>
<tr class="odd">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>NS3/4 protease inhibitor inclusive regimen (e.g. Zepatier)</td>
<td>2002</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Mavyret</td>
<td>2003</td>
</tr>
<tr class="odd">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Vosevi or sofosbuvir + Mavyret</td>
<td>2004</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>GT 3 only: sofosbuvir/NS5A (e.g. Harvoni)</td>
<td>2005</td>
</tr>
<tr class="odd">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Other</td>
<td>1235</td>
</tr>
<tr class="even">
<td>19</td>
<td>2001</td>
<td></td>
<td>Select and Free Text</td>
<td><p>The Ohio Department of Medicaid allows the following treatment regimens. Please select the regimen you are requesting.</p>
<p>If other, please enter drug regimen requested, including drug names, doses, and duration of treatment.</p></td>
<td>Mavyret 100/40 mg, three (3) tablets daily for 16 weeks</td>
<td>1225</td>
</tr>
<tr class="odd">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Other</td>
<td>1225</td>
</tr>
<tr class="even">
<td>20</td>
<td>2002</td>
<td></td>
<td>Select and Free Text</td>
<td><p>The Ohio Department of Medicaid allows the following treatment regimens. Please select the regimen you are requesting.</p>
<p>If other, please enter drug regimen requested, including drug names, doses, and duration of treatment.</p></td>
<td>Vosevi 400/100/100 mg, one tablet daily for 12 weeks</td>
<td>1225</td>
</tr>
<tr class="odd">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Other</td>
<td>1225</td>
</tr>
<tr class="even">
<td>21</td>
<td>2003</td>
<td></td>
<td>Select and Free Text</td>
<td><p>The Ohio Department of Medicaid allows the following treatment regimens. Please select the regimen you are requesting.</p>
<p>If other, please enter drug regimen requested, including drug names, doses, and duration of treatment.</p></td>
<td>Vosevi 400/100/100 mg, one tablet daily for 12 weeks (if compensated cirrhosis, add weight-based RBV)</td>
<td>1225</td>
</tr>
<tr class="odd">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Other</td>
<td>1225</td>
</tr>
<tr class="even">
<td>22</td>
<td>2004</td>
<td></td>
<td>Select and Free Text</td>
<td><p>The Ohio Department of Medicaid allows the following treatment regimens. Please select the regimen you are requesting.</p>
<p>If other, please enter drug regimen requested, including drug names, doses, and duration of treatment.</p></td>
<td>Vosevi 400/100/100 mg, one tablet daily + weight-based RBV for 24 weeks</td>
<td>1225</td>
</tr>
<tr class="odd">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Other</td>
<td>1225</td>
</tr>
<tr class="even">
<td>23</td>
<td>2005</td>
<td></td>
<td>Select and Free Text</td>
<td><p>The Ohio Department of Medicaid allows the following treatment regimens. Please select the regimen you are requesting.</p>
<p>If other, please enter drug regimen requested, including drug names, doses, and duration of treatment.</p></td>
<td>Vosevi 400/100/100 mg, one tablet daily + weight-based RBV for 12 weeks</td>
<td>1225</td>
</tr>
<tr class="odd">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Other</td>
<td>1225</td>
</tr>
<tr class="even">
<td>24</td>
<td>3000</td>
<td></td>
<td>Select</td>
<td>Please select from one of the following:</td>
<td>Direct Acting Antivirals (DAA)-treatment naïve, no decompensated cirrhosis</td>
<td>3001</td>
</tr>
<tr class="odd">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Direct Acting Antivirals (DAA)-treatment experienced, no decompensated cirrhosis</td>
<td>3002</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Direct Acting Antivirals (DAA)-treatment experienced, multiple negative baseline characteristics</td>
<td>3003</td>
</tr>
<tr class="odd">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Treatment naïve, decompensated cirrhosis</td>
<td>3004</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Treatment experienced, decompensated cirrhosis (Child-Pugh B or C ONLY)</td>
<td>3005</td>
</tr>
<tr class="odd">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Other</td>
<td>1235</td>
</tr>
<tr class="even">
<td>25</td>
<td>3001</td>
<td></td>
<td>Select and Free Text</td>
<td><p>The Ohio Department of Medicaid allows the following treatment regimens. Please select the regimen you are requesting.</p>
<p>If other, please enter drug regimen requested, including drug names, doses, and duration of treatment.</p></td>
<td>Mavyret 100/40 mg, three (3) tablets daily for 12 weeks</td>
<td>1231</td>
</tr>
<tr class="odd">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>sofosbuvir/velpatasvir 400/100 mg, one tablet daily for 12 weeks</td>
<td>1231</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Other</td>
<td>1228</td>
</tr>
<tr class="odd">
<td>26</td>
<td>3002</td>
<td></td>
<td>Select and Free Text</td>
<td><p>The Ohio Department of Medicaid allows the following treatment regimens. Please select the regimen you are requesting.</p>
<p>If other, please enter drug regimen requested, including drug names, doses, and duration of treatment.</p></td>
<td>Vosevi 400/100/100 mg, one tablet daily for 12 weeks</td>
<td>1225</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Other</td>
<td>1225</td>
</tr>
<tr class="odd">
<td>27</td>
<td>3003</td>
<td></td>
<td>Select and Free Text</td>
<td><p>The Ohio Department of Medicaid allows the following treatment regimens. Please select the regimen you are requesting.</p>
<p>If other, please enter drug regimen requested, including drug names, doses, and duration of treatment.</p></td>
<td>Vosevi 400/100/100 mg, one tablet daily + low dose RBV for 12 weeks</td>
<td>1225</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Other</td>
<td>1225</td>
</tr>
<tr class="odd">
<td>28</td>
<td>3004</td>
<td></td>
<td>Select</td>
<td>The Ohio Department of Medicaid allows the following treatment regimens. Please select the regimen you are requesting.</td>
<td>sofosbuvir/velpatasvir 400/100 mg, one tablet daily + low dose RBV for 12 weeks</td>
<td>1231</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Other</td>
<td>1228</td>
</tr>
<tr class="odd">
<td>29</td>
<td>3005</td>
<td></td>
<td>Select and Free Text</td>
<td><p>The Ohio Department of Medicaid allows the following treatment regimens. Please select the regimen you are requesting.</p>
<p>If other, please enter drug regimen requested, including drug names, doses, and duration of treatment.</p></td>
<td>sofosbuvir/velpatasvir 400/100 mg, one tablet daily + low dose RBV for 24 weeks</td>
<td>1225</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Other</td>
<td>1225</td>
</tr>
<tr class="odd">
<td>30</td>
<td>4000</td>
<td></td>
<td>Select</td>
<td>Please select the regimen previously used:</td>
<td>No prior sofosbuvir or NS5A failure</td>
<td>4001</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Prior sofosbuvir or NS5A failure</td>
<td>4002</td>
</tr>
<tr class="odd">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Other</td>
<td>1235</td>
</tr>
<tr class="even">
<td>31</td>
<td>4001</td>
<td></td>
<td>Select and Free Text</td>
<td><p>The Ohio Department of Medicaid allows the following treatment regimens. Please select the regimen you are requesting.</p>
<p>If other, please enter drug regimen requested, including drug names, doses, and duration of treatment.</p></td>
<td>sofosbuvir/velpatasvir 400/100 mg + weight-based RBV daily for 12 weeks (low dose RBV recommended for Child-Pugh class C cirrhosis)</td>
<td>1231</td>
</tr>
<tr class="odd">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>sofosbuvir/velpatasvir 400/100 mg daily for 24 weeks (will be approved only for patients with documented ineligibility for RBV)</td>
<td>1231</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Other</td>
<td>1228</td>
</tr>
<tr class="odd">
<td>32</td>
<td>4002</td>
<td></td>
<td>Select and Free Text</td>
<td><p>The Ohio Department of Medicaid allows the following treatment regimens. Please select the regimen you are requesting.</p>
<p>If other, please enter drug regimen requested, including drug names, doses, and duration of treatment.</p></td>
<td>sofosbuvir/velpatasvir 400/100 mg + weight-based RBV daily for 24 weeks (low dose RBV if Child-Pugh C)</td>
<td>1225</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Other</td>
<td>1225</td>
</tr>
<tr class="odd">
<td>33</td>
<td>1225</td>
<td></td>
<td>Select and Free Text</td>
<td><p>Has the provider submitted documentation of the following:</p>
<p>Prior treatment regimens, dates &amp; outcomes, including reason for failure, if known (e.g. failed to complete prior therapy, failure of past therapy)?</p></td>
<td>Y</td>
<td>1228</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1235</td>
</tr>
<tr class="odd">
<td>34</td>
<td>1228</td>
<td></td>
<td>Select and Free Text</td>
<td><p>Has the provider submitted documentation of the patient’s genotype, treatment history, and extent of liver disease?</p>
<p>If yes, please submit documentation.</p></td>
<td>Y</td>
<td>1229</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1235</td>
</tr>
<tr class="odd">
<td>35</td>
<td>1229</td>
<td></td>
<td>Select</td>
<td>Is the provider requesting a regimen that is not outlined by the Ohio Department of Medicaid (I.e. If selected “Other” for regimen during previous questions)?</td>
<td>Y</td>
<td>1230</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1231</td>
</tr>
<tr class="odd">
<td>36</td>
<td>1230</td>
<td></td>
<td>Select and Free Text</td>
<td><p>Has the provider submitted clinical rationale for selecting regimens other than those outlined by the Ohio Department of Medicaid?</p>
<p>If yes, please submit documentation.</p></td>
<td>Y</td>
<td>1231</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1235</td>
</tr>
<tr class="odd">
<td>37</td>
<td>1231</td>
<td></td>
<td>Select</td>
<td>Is this request being prescribed in accordance with Food and Drug Administration (FDA) approved labeling? </td>
<td>Y</td>
<td>1232</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1235</td>
</tr>
<tr class="odd">
<td>38</td>
<td>1232</td>
<td></td>
<td>Select</td>
<td>Is this request being prescribed in accordance with a regimen recommended by the American Association for the Study of Liver Diseases (AASLD)?   </td>
<td>Y</td>
<td>1233</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1235</td>
</tr>
<tr class="odd">
<td>39</td>
<td>1233</td>
<td></td>
<td>Select and Free Text</td>
<td><p>Is the request for a preferred medication?</p>
<p>Please note, the preferred medications are:</p>
<ul>
<li><p>Mavyret, Pegasys, Ribavirin, Sofosbuvir/Velpatasvir</p></li>
</ul>
<p>Please note: Regimens including pegylated Interferons must include close monitoring with periodic clinical and laboratory evaluations.</p></td>
<td>Y</td>
<td>END (Pending Manual Review)</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>8998</td>
</tr>
<tr class="odd">
<td>40</td>
<td>8998</td>
<td></td>
<td>Select and Free Text</td>
<td><p>Has the patient had an inadequate clinical response defined as not achieving SVR with guideline-recommended preferred drugs?</p>
<p>If yes, please submit the medication trials and dates.</p></td>
<td>Y</td>
<td>9000</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>8999</td>
</tr>
<tr class="odd">
<td>41</td>
<td>8999</td>
<td></td>
<td>Select and Free Text</td>
<td><p>Has the provider submitted documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances)?</p>
<p>Requests for patients established on current therapy with prior payer (i.e., Commercial, Fee-for-Service, Managed Care Plan, etc) will be authorized with documentation.</p>
<p>If yes, please submit the medication name and reason for inability to use.</p></td>
<td>Y  </td>
<td>9000</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N  </td>
<td>1236</td>
</tr>
<tr class="odd">
<td>42</td>
<td>9000</td>
<td></td>
<td>Select</td>
<td><p>Is the request for any of the following:</p>
<p>1) a nonsolid oral dosage formulation</p>
<p>2) a non-preferred extended release formulation</p>
<p>3) a non-preferred brand name that has a preferred generic product</p></td>
<td>Y</td>
<td>9001</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>END (Pending Manual Review)</td>
</tr>
<tr class="odd">
<td>43</td>
<td>9001</td>
<td></td>
<td>Select and Free Text</td>
<td>Has the provider submitted documentation of medical necessity for the requested product (i.e. medical reasons for why the patient cannot be changed to a solid oral dosage formulation, inadequate clinical response with a product’s immediate release formulation, or inadequate clinical response or allergy of two or more generic labelers)?</td>
<td>Y</td>
<td>END (Pending Manual Review)</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1235</td>
</tr>
<tr class="odd">
<td>44</td>
<td>1235</td>
<td></td>
<td>Free Text</td>
<td>Please provide the rationale for the medication being requested. </td>
<td>END (Pending Manual Review)</td>
<td></td>
</tr>
<tr class="even">
<td>45</td>
<td>1236</td>
<td></td>
<td>Free Text</td>
<td>Please explain the reason(s) why the patient is unable to use medications not requiring prior approval.</td>
<td>END (Pending Manual Review)</td>
<td></td>
</tr>
</tbody>
</table>

LENGTH OF AUTHORIZATIONS: Up to the length authorized by the American
Association for the Study of Liver Disease (AASLD) guidelines.

| **Last Approved** | 10/24/2023                                                                                                                                                           |
| ----------------- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| **Other**         | INTERNAL NOTE: Please evaluate the patient’s regimen and authorize other applicable agents such as ribavirin (if appropriate). Please notify prescriber accordingly. |
